ماروبيتانت

Dogs (2-4 Months of Age)

For Prevention and Treatment of Acute Vomiting in Dogs: Dogs 2-4 Months of Age:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Dogs (4 Months of Age and Older)

For Prevention of Vomiting in Dogs 4 months of Age and Older Caused by Emetogenic Medications or Chemotherapeutic Agents.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Dogs (4 Months of Age and Older)

For Prevention and Treatment of Acute Vomiting in Dogs: Dogs 2-4 Months of Age:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Dogs (4 Months of Age and Older)

For the prevention of vomiting due to motion sickness.

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. CERENIA injectable solution should not be used interchangeably with CERENIA tablets for the prevention of vomiting due to motion sickness (8mg/kg).

Cerenia® Tablets

Dogs (7 Months of Age and Older)

For the prevention of acute vomiting.

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cerenia® Tablets

Dogs (2-7 Months)

For the prevention of acute vomiting.

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cerenia® Tablets

Dogs (2-7 months of age)

For prevention of acute vomiting.

Maropitant Citrate

Dogs (7 months of age and older)

For prevention of acute vomiting.

Maropitant Citrate

Dogs (4 months of age and older)

For prevention of vomiting due to motion sickness.

Maropitant Citrate

For the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Maropitant Citrate Tablets

For the prevention and treatment of acute vomiting.

Maropitant Citrate

Cats (4 Months of Age and Older)

For Treatment of Vomiting in Cats 4 Months of Age and Older

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

For the treatment of vomiting.

Maropitant Citrate

Prevention of Acute Vomiting: Used to prevent vomiting associated with various causes, including surgery, chemotherapy, and gastrointestinal disorders. Treatment of Motion Sickness: Effective in managing vomiting induced by motion sickness in dogs. Suitable for dogs, cats, and other pets.

Xile, AWQYYSL Pet Motion Sickness Tablets, 16 / 24 / 60mg *10 tablets each box

Dogs: CERENIA (maropitant citrate) Injectable Solution is indicated for the prevention and treatment of acute vomiting in dogs. Cats: CERENIA (maropitant citrate) Injectable Solution is indicated for the treatment of vomiting in cats.

Cerenia® (maropitant citrate) Injectable Solution

Dogs: Emeprev (maropitant citrate) Injectable Solution is indicated for the prevention and treatment of acute vomiting in dogs. Cats: Emeprev (maropitant citrate) Injectable Solution is indicated for the treatment of vomiting in cats.

Emeprev™(maropitant citrate)Injectable Solution

INDICATIONS: Emeprev (maropitant citrate) Tablets are indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs.

Emeprev™ (maropitant citrate) Tablets

Pharmacokinetics Mean (±SD) Plasma Pharmacokinetic Parameters for Maropitant in Beagle Dogs after single dose and repeat oral doses of Maropitant: PK Parameter 2 mg/kg Single Dose 2 mg/kg repeat Doses1 8 mg/kg Single Dose 8 mg/kg repeat Doses1 Tmax 2 (hr) 2.0 (1.5 – 3.0) 1.5 (1.0 – 3.0) 1.5 (1.0 – 3.0) 2.5 (1.5 – 7.0) Cmax (ng/mL) 154 (111) 304 (165) 588 (416) 1409 (516) AUC(0-24) (ng*hr/mL) 1440 (982) 3890 (3030) 6730 (5030) 26600 (9200) T1/2 2 (hr) NC 7.69 (6.21 - 17.8) NC 25.4 (6.06 - 30.0) Accumulation Ratio (Rac)3 NA 2.46 (1.68, 3.61) NA 4.81 (3.28, 7.05) 1Following once daily doses of maropitant for 14 days. 2Median (Range) 3Ratio=Multiple Dose AUC(0-24)/Single Dose AUC(0-24), Least square means (95% Confidence Interval) NA= Not Applicable NC= Not Calculated Following oral administration, median time to reach Cmax was within 2.5 hr. The absolute bioavailability of maropitant was low (24%) following oral administration of 2 mg/kg maropitant. After an oral dose, prandial status does not significantly affect the extent of oral bioavailability. Greater than dose-proportional drug exposure can be expected with an increase in dose (1-16 mg/kg PO). However as doses increase (20-50 mg/kg PO), the dose proportionality is re-established. Based upon in vitro enzyme kinetics, involvement of a high capacity enzyme (CYP3A12) may contribute to this return to dose linearity. Due to dose dependent pharmacokinetics, the maropitant concentrations reached steady state approximately after 4 and 8 days following 2 and 8 mg/kg, respectively. The observed drug accumulation ratios were 2.46 and 4.81, after oral administration of 2 and 8 mg/kg, respectively. The exposure of 10 week old puppies to maropitant was lower than that observed in adult dogs, particularly after repeat doses of 1 or 2 mg/kg. Systemic clearance of maropitant following IV administration was 970, 995, and 533 mL/hr/kg at doses of 1, 2 and 8 mg/kg, respectively. Urinary recovery of maropitant and its major metabolite was minimal (<1% each). The hepatic metabolism of maropitant involves two cytochrome P-450 isoenzymes: CYP2D15 and CYP3A12. In in vitro enzyme kinetics data suggest that the non-linear kinetics may be partially associated with saturation of the low capacity enzyme (CYP2D15). Plasma protein binding of maropitant was high (99.5%). Pharmacodynamics Vomiting is a complex process coordinated centrally by the emetic center which consists of several brainstem nuclei (area postrema, nucleus tractus solitarius, dorsal motor nucleus of the vagus) that receive and integrate sensory stimuli from central and peripheral sources and chemical stimuli from the circulation and the cerebro-spinal fluid. Maropitant is a neurokinin 1 (NK1) receptor antagonist which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family. Substance P is found in significant concentrations in the nuclei comprising the emetic center and is considered the key neurotransmitter involved in emesis.1By inhibiting the binding of substance P within the emetic center, maropitant provides broad-spectrum effectiveness against neural (central) and humoral (peripheral) causes of vomiting. In vivo model studies in dogs have shown that maropitant has antiemetic effectiveness against both central and peripheral emetogens including apomorphine, and syrup of ipecac. 1Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. [Review] [60 refs]. Drugs. 2000;60:533-46. EFFECTIVENESS Prevention of Acute Vomiting In laboratory model studies, maropitant citrate tablets dosed at a minimum of 2 mg/kg BW reduced the number of emetic events associated with established neural (central) and humoral (peripheral) stimuli. Following administration of apomorphine (central emetic stimuli), vomiting was observed in 33% (4 of 12) of Beagle dogs treated with maropitant citrate tablets and 100% (12 of 12) of Beagle dogs treated with placebo tablets. Following administration of syrup of ipecac (peripheral emetic stimuli) vomiting was observed in 33% (4 of 12) of Beagle dogs treated with maropitant citrate tablets and in 83% (10 of 12) of Beagle dogs treated with placebo tablets. In a study of 275 canine patients presented to veterinary hospitals with a history of acute vomiting, dogs were initially administered maropitant citrate injectable solution or placebo on Day 0. Following the initial dose, dogs allocated to the maropitant citrate group were treated with either maropitant citrate tablets at a minimum of 2 mg/kg orally or injectable solution at 1 mg/kg subcutaneously once daily at the discretion of the clinician. Dogs allocated to the placebo group were treated using either an injectable placebo solution or placebo tablets once daily at the discretion of the clinician. Of the 199 dogs included in the analysis for effectiveness, 27 of 54 dogs (50%) in the placebo group displayed vomiting at some time during the study and 31 of 145 dogs (21.4%) in the treated group displayed vomiting during the study period. Percent Of Vomiting For Each Study Day, Based Upon Treatment And Route Of Administration. Days Treatment Route # dogs # vomited % vomited Day 0 Placebo (54) SC 54 15 28% maropitant citrate (145) SC 145(143*) 14 10% Day 1 Placebo (45) PO 22 3 14% SC 23 16 70% maropitant citrate (108) PO 67 2 3% SC 41 16 39% Day 2 Placebo (16) PO 7 2 29% SC 9 6 67% maropitant citrate (37) PO 24 0 0% SC 13 8 62% Day 3 Placebo (6) PO 2 0 0% SC 4 1 25% maropitant citrate (21) PO 14 0 0% SC 7 5 71% Day 4 Placebo (2) PO 1 0 0% SC 1 1 100% maropitant citrate (7) PO 5 0 0% SC 2 1 50% Day 5 maropitant citrate (1) SC 1 0 0% *2 dogs administered maropitant citrate were not observed on Day 0. Their vomiting status was unknown. 143 was used in the denominator for % vomited. In US field studies in veterinary patients, maropitant citrate tablets and injectable solution were well tolerated in dogs presenting with various conditions including parvovirus, gastroenteritis, and renal disease. There were no notable differences in mean laboratory values between maropitant citrate -treated and placebo-treated patients. Maropitant citrate tablets were used safely in dogs receiving other frequently used veterinary products such as fluid and electrolyte replacement solutions, antimicrobial agents, vaccines, antacids, and antiparasitic agents. Prevention of Vomiting due to Motion Sickness In a study of canine veterinary patients taken on a one-hour car journey and treated with either maropitant citrate tablets at a minimum dose of 8 mg/kg BW or placebo tablets 2 hours prior to the journey, 67 of 122 (55%) of dogs vomited during the journey when treated with placebo while 8 of 122 (7%) vomited during the journey after treatment with maropitant citrate tablets. The probability that a dog in this study, prone to motion sickness would NOT vomit during a journey if treated with maropitant citrate tablets was 93%, while the probability was 48% if treated with placebo.

CeritantTM (maropitanat citrate) Tablets

Do not use in pets with a known allergy to any of the ingredients.

Xile, AWQYYSL Pet Motion Sickness Tablets, 16 / 24 / 60mg *10 tablets each box

Not for use in humans. Keep out of the reach of children. In case of accidental ingestion, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. Wash hands with soap and water after administering drug. Ceritant (maropitant citrate) Tablets is also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention. Keep Ceritant (maropitant citrate) Tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. In puppies younger than 11 weeks of age, histological evidence of bone marrow hypocellularity was observed at higher frequency and greater severity in puppies treated with Ceritant (maropitant citrate) Tablets compared to control puppies. In puppies 16 weeks and older, bone marrow hypocellularity was not observed (see ANIMAL SAFETY).

CeritantTM (maropitanat citrate) Tablets

Not for use in humans. Keep out of the reach of children. In case of accidental ingestion, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. Wash hands with soap and water after administering drug. Maropitant Citrate Tablets are also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention. In puppies younger than 11 weeks of age, histological evidence of bone marrow hypocellularity was observed at higher frequency and greater severity in puppies treated with maropitant citrate compared to control puppies. In puppies 16 weeks and older, bone marrow hypocellularity was not observed (see ANIMAL SAFETY ). Keep Maropitant Citrate Tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Maropitant Citrate Tablets Antiemetic For oral use in dogs only

WARNINGS: Not for use in humans. Keep out of the reach of children. In case of accidental ingestion, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. Wash hands with soap and water after administering drug. Emeprev is also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention. In puppies younger than 11 weeks of age, histological evidence of bone marrow hypocellularity was observed at higher frequency and greater severity in puppies treated with maropitant citrate compared to control puppies. In puppies 16 weeks and older, bone marrow hypocellularity was not observed (see ANIMAL SAFETY ). Keep Emeprev Tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Emeprev™ (maropitant citrate) Tablets

Not for use in humans. Keep out of reach of children. In case of accidental injection or exposure, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. In case of accidental skin exposure, wash with soap and water. Emeprev Injectable Solution is also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention. In puppies younger than 11 weeks of age, histological evidence of bone marrow hypocellularity was observed at higher frequency and greater severity in puppies treated with maropitant citrate compared to control puppies. In puppies 16 weeks and older, bone marrow hypocellularity was not observed (see ANIMAL SAFETY).

Emeprev™(maropitant citrate)Injectable Solution

Not for use in humans. Keep out of the reach of children. In case of accidental ingestion, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. Wash hands with soap and water after administering drug. CERENIA is also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention. In puppies younger than 11 weeks of age, histological evidence of bone marrow hypocellularity was observed at higher frequency and greater severity in puppies treated with CERENIA compared to control puppies. In puppies 16 weeks and older, bone marrow hypocellularity was not observed (see ANIMAL SAFETY).

Cerenia® (maropitant citrate) Tablets

This product is for veterinary use only. Do not administer to humans. Keep out of reach of children. Do not exceed the recommended dosage.

Xile, AWQYYSL Pet Motion Sickness Tablets, 16 / 24 / 60mg *10 tablets each box

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Emeprev™ (maropitant citrate) Tablets

Prevention of Acute Vomiting (minimum of 2 mg/kg) The following adverse reactions were reported during the course of a US field study for the prevention of acute vomiting in dogs treated with maropitant citrate tablets at a minimum of 2 mg/kg orally and/or injectable solution at 1 mg/kg subcutaneously once daily for up to 5 consecutive days: Frequency of Adverse Reactions by Treatment Adverse Reaction Placebo (n=69) Maropitant citrate (n=206) # dogs % occurrence # dogs % occurrence Death during study 4 5.8 10 4.9 Euthanized during study 0 0 2 1 Diarrhea 6 8.7 8 3.9 Hematochezia/bloody stool 5 7.2 4 1.9 Anorexia 2 2.9 3 1.5 Otitis/Otorrhea 0 0 3 1.5 Endotoxic Shock 1 1.4 2 1 Hematuria 0 0 2 1 Excoriation 0 0 2 1 Other clinical signs were reported but were <0.5% of dogs. Prevention of Vomiting Due to Motion Sickness (minimum of 8 mg/kg) The following adverse reactions were reported during US studies for the prevention of vomiting due to motion sickness in dogs treated with maropitant citrate tablets at a minimum of 8 mg/kg orally one time. Dogs may have experienced more than one of the observed adverse reactions. Frequency of Adverse Reactions by Treatment Adverse Reaction Placebo (n=195) Maropitant citrate (n=208) # dogs % occurrence # dogs % occurrence Hypersalivation 19 9.7 26 12.5 Vomiting* 0 0 11 5.3 Muscle Tremors 1 0.5 2 1 Sedation/Depression 3 1.5 2 1 Retching 3 1.5 1 0.5 Flatulence 0 0 1 0.5 *Not associated with motion sickness. The following adverse reactions were reported during a European field study for the prevention of vomiting due to motion sickness in dogs treated with maropitant citrate tablets at a minimum of 8 mg/kg orally once daily for 2 consecutive days. Dogs may have experienced more than one of the observed adverse reactions. Frequency of Adverse Reactions by Treatment Adverse Reaction Placebo (n=106) Maropitant citrate (n=107) # dogs % occurrence # dogs % occurrence Vomiting 4 4 10 9 Drowsiness/Lethargy/Apathy 1 1 8 8 Hypersalivation 2 2 5 5 Anxiety 0 0 2 2 Trembling/Tremors 0 0 2 2 Inappetence 0 0 2 2 Mucus in stool 0 0 1 1 The following Adverse Reactions were reported during the conduct of a US clinical field trial where maropitant citrate tablets were administered once daily for 28 consecutive days to 32 dogs: lethargy, vomiting, inappetence, corneal edema, and enlarged lymph nodes. Post-Approval Experience (Revised May 2019) The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse events are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events reported for dogs are listed in decreasing order of frequency: anorexia, depression/lethargy, hypersalivation, vomiting, diarrhea, trembling, ataxia, allergic reactions, weight loss, convulsion, hyperactivity, and panting. Cases of ineffectiveness have been reported. Cases of death (including euthanasia) have been reported. Contact Information Contact Felix Pharmaceuticals Private Limited at 1-833-571-1525 or www.felixvet.com.To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Felix Pharmaceuticals Private Limited at 1-833-571-1525. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae To obtain Safety Data Sheet(s), contact Felix Pharmaceuticals Private Limited at 1-833-571-1525.

Maropitant Citrate Tablets Chewable Tablets Antiemetic For oral use in dogs only

Mild side effects such as drowsiness or dry mouth may occur in some pets. These symptoms typically resolve on their own and do not require treatment. If severe side effects occur, stop use immediately and consult a veterinarian.

Xile, AWQYYSL Pet Motion Sickness Tablets, 16 / 24 / 60mg *10 tablets each box

Dogs (2-4 Months of Age)

Administer subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/kg (0.1 mL/2.2 lb) of body weight once daily for up to 5 consecutive days.

Subcutaneous, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Dogs (4 Months of Age and Older)

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) of body weight one time, 45-60 minutes prior to use of emetogenic medications or chemotherapeutic agents.

Subcutaneous, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Dogs (4 Months of Age and Older)

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/1 kg (1 mL/22 lb) of body weight once daily for up to 5 consecutive days.

Subcutaneous, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Dogs (4 Months of Age and Older)

Administer CERENIA Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days

Oral

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. CERENIA injectable solution should not be used interchangeably with CERENIA tablets for the prevention of vomiting due to motion sickness (8mg/kg).

Cerenia® Tablets

Dogs (7 Months of Age and Older)

Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Oral

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cerenia® Tablets

Dogs (2-7 Months)

Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days

Oral

For oral use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cerenia® Tablets

Dogs (2-7 months of age)

Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days.

Oral

Maropitant Citrate

Dogs (7 months of age and older)

Administer orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.

Oral

Maropitant Citrate

Dogs (4 months of age and older)

Administer orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.

Oral

Maropitant Citrate

For Prevention of Acute Vomiting in dogs 2 - 7 months of age: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days. For Prevention of Acute Vomiting in dogs 7 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting. For Prevention of Vomiting due to motion sickness in dogs 4 months of age and older: Administer Maropitant Citrate Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days.

Oral

Maropitant Citrate Tablets

Administer 1.0 mg per kilogram (mg/kg) of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.

Intravenous, Subcutaneous

Maropitant Citrate

Cats (4 Months of Age and Older)

Administer intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/kg (0.1 mL/2.2 lb) of body weight once daily for up to 5 consecutive days.

Subcutaneous, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats with gastrointestinal obstruction or that have ingested toxins. The safe use of CERENIA Injectable Solution has not been evaluated in dogs or cats used for breeding, or in pregnant or lactating bitches or queens.

Cerenia® Injectable Solution

Administer 1.0 mg/kg of body weight by subcutaneous or intravenous injection once daily for up to 5 consecutive days.

Intravenous, Subcutaneous

Maropitant Citrate

Select the appropriate tablet strength and dosage based on your pet’s weight: For prevention of acute vomiting, dispense whole or half tablets in strength(s) that most closely result in a 2 mg/kg dose. Administration Time: Administer the tablet 2 hour before travel for optimal effectiveness. Once daily, up to 5 days. Administration Method: Place the tablet directly into your pet's mouth.

ORAL

Xile, AWQYYSL Pet Motion Sickness Tablets, 16 / 24 / 60mg *10 tablets each box

Use of refrigerated product may reduce the pain response associated with subcutaneous injection.

INTRAVENOUS, SUBCUTANEOUS

Cerenia® (maropitant citrate) Injectable Solution